Replies to post #245467 on Avid Bioservices Inc (CDMO)

[JamesGMS]

CJ, you just posted the following: ATTN: MH

12-10-15 STEVE KING(Q&A): “The [further Avid] expansion really is driven by our existing and new clients that have come in, and so obviously primarily that’s driven in the bulk drug substances area not necessarily the fill/finish area. So that'll probably be the primary focus; we have considered and eventually would like to move into the fill/finished business, it's just we’ve been so busy expanding our drug substances business, we really haven’t had the option to do that.

A member of our group would like to more thoroughly understand the terms SK utilized - therefore, could anyone {MH ??} provide a clear explanation of the terms "bulk drug substance area" VS "fill/finish area" - and then whether the expansion into the second area of expertise might effect or in any way play a role in the commercialization process for Bavi.

Thanks for your input. And thanks again to CJ for all your valuable contributions.

James

[DewDiligence]

Maybe B-I, but that's just a wild guess.